No Data
Oppenheimer Maintains OnKure Therapeutics(OKUR.US) With Buy Rating, Maintains Target Price $35
Express News | Onkure Therapeutics Inc - No Dose Interruptions, Delays, Reductions, or Discontinuations Reported
Express News | Onkure Therapeutics Inc - Oki-219 Well Tolerated With No Hyperglycemia and Only Grade 1 Traes
Express News | Onkure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (Pk) Data From Its First-in-Human Pikture-01 Trial of Oki-219
Leerink Partners Initiates OnKure Therapeutics(OKUR.US) With Buy Rating, Announces Target Price $33
Leerink Partners Initiates Coverage On OnKure Therapeutics With Outperform Rating, Announces Price Target of $33
No Data
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
